TG Therapeutics (TGTX) Announces Earnings Results, Beats Expectations By $0.12 EPS

TG Therapeutics (NASDAQ:TGTX) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.12, MarketWatch Earnings reports. TG Therapeutics had a negative net margin of 97,412.51% and a negative return on equity of 177.79%.

Shares of NASDAQ:TGTX opened at $5.54 on Friday. TG Therapeutics has a one year low of $4.20 and a one year high of $17.35.

A number of equities research analysts recently weighed in on the stock. Raymond James cut shares of TG Therapeutics from a “strong-buy” rating to an “outperform” rating and reduced their price target for the company from $22.00 to $12.00 in a research report on Tuesday, September 25th. BidaskClub cut shares of TG Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, July 20th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of TG Therapeutics in a report on Friday, November 2nd. ValuEngine raised shares of TG Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, October 24th. Finally, LADENBURG THALM/SH SH set a $27.00 target price on shares of TG Therapeutics and gave the company a “buy” rating in a report on Wednesday, September 26th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the stock. TG Therapeutics presently has a consensus rating of “Hold” and an average price target of $21.75.

Several large investors have recently made changes to their positions in the company. BlackRock Inc. raised its holdings in shares of TG Therapeutics by 8.3% in the third quarter. BlackRock Inc. now owns 4,420,852 shares of the biopharmaceutical company’s stock valued at $24,757,000 after buying an additional 339,802 shares during the last quarter. RA Capital Management LLC raised its holdings in shares of TG Therapeutics by 73.1% in the second quarter. RA Capital Management LLC now owns 4,278,796 shares of the biopharmaceutical company’s stock valued at $56,266,000 after buying an additional 1,806,452 shares during the last quarter. Wells Fargo & Company MN raised its holdings in shares of TG Therapeutics by 2,148.1% in the second quarter. Wells Fargo & Company MN now owns 888,768 shares of the biopharmaceutical company’s stock valued at $11,686,000 after buying an additional 849,233 shares during the last quarter. Northern Trust Corp raised its holdings in shares of TG Therapeutics by 19.3% in the second quarter. Northern Trust Corp now owns 751,725 shares of the biopharmaceutical company’s stock valued at $9,885,000 after buying an additional 121,424 shares during the last quarter. Finally, Candriam Luxembourg S.C.A. raised its holdings in shares of TG Therapeutics by 62.8% in the third quarter. Candriam Luxembourg S.C.A. now owns 692,000 shares of the biopharmaceutical company’s stock valued at $3,875,000 after buying an additional 267,000 shares during the last quarter. 48.31% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: “TG Therapeutics (TGTX) Announces Earnings Results, Beats Expectations By $0.12 EPS” was originally reported by WKRB News and is owned by of WKRB News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.wkrb13.com/2018/11/10/tg-therapeutics-tgtx-announces-earnings-results-beats-expectations-by-0-12-eps.html.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.

Featured Article: What is a Tariff?

Earnings History for TG Therapeutics (NASDAQ:TGTX)

Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply